Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1830034rdf:typepubmed:Citationlld:pubmed
pubmed-article:1830034lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0441833lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0016343lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C1999270lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C1514485lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:1830034lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:1830034pubmed:issue5lld:pubmed
pubmed-article:1830034pubmed:dateCreated1991-8-20lld:pubmed
pubmed-article:1830034pubmed:abstractTextGamma-Interferon (IFN-gamma) and the antimetabolites 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FUdR) were investigated as individual agents and in combination for their in vitro antiproliferative capacity and for their effect on the expression of HLA class-I antigen, carcinoembryonic antigen (CEA) and the intracellular tumor-associated antigen CTA-I in 7 human colorectal cancer cell lines: WiDr, HT29, Colo 205, SW116, LS174T, SW1398, and LoVo. Growth inhibition by IFN-gamma at clinically relevant concentrations (50-100 U/ml) was found in 4/7 cell lines. The cell lines were equally sensitive to 5-FU (IC50 in a range of 2-10 microM), while sensitivity to FUdR varied considerably (IC50 in a range of 0.01-90 microM). When 50 U/ml IFN-gamma were combined with 5-FU or FUdR, the antiproliferative effects were synergistic in those cell lines with sensitivity to IFN-gamma as a single agent, but not in the IFN-gamma-insensitive cell lines. IFN-gamma was able to enhance the expression of HLA Class I and CEA in 4/7 and 3/7 cell lines, respectively, as measured by flow cytometry. CTA-I expression could not be enhanced with IFN-gamma. The expression of the 3 antigens tested was also increased by 5-FU and FUdR. This effect was concentration-dependent in most instances and varied between the individual cell lines. The combination of 50 U/ml IFN-gamma with 25% growth-inhibitory concentration of 5-FU or FUdR for each cell line resulted in an additional increase in antigen expression in 4/7 cell lines. No relation was found between the enhancement of antigen expression and the sensitivity to IFN-gamma or the anti-metabolites. The enhancement in antigen expression also did not show a relationship with changes in cell-cycle distribution upon exposure to IFN-gamma or the anti-metabolites. These results suggest independent mechanisms for the antiproliferative and antigen-enhancing effects of IFN-gamma, 5-FU and FUdR.lld:pubmed
pubmed-article:1830034pubmed:languageenglld:pubmed
pubmed-article:1830034pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:citationSubsetIMlld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1830034pubmed:statusMEDLINElld:pubmed
pubmed-article:1830034pubmed:monthJullld:pubmed
pubmed-article:1830034pubmed:issn0020-7136lld:pubmed
pubmed-article:1830034pubmed:authorpubmed-author:PinedoH MHMlld:pubmed
pubmed-article:1830034pubmed:authorpubmed-author:BovenEElld:pubmed
pubmed-article:1830034pubmed:authorpubmed-author:HaismaH JHJlld:pubmed
pubmed-article:1830034pubmed:authorpubmed-author:LinnW DWDlld:pubmed
pubmed-article:1830034pubmed:authorpubmed-author:SchlüperH MHMlld:pubmed
pubmed-article:1830034pubmed:issnTypePrintlld:pubmed
pubmed-article:1830034pubmed:day9lld:pubmed
pubmed-article:1830034pubmed:volume48lld:pubmed
pubmed-article:1830034pubmed:ownerNLMlld:pubmed
pubmed-article:1830034pubmed:authorsCompleteYlld:pubmed
pubmed-article:1830034pubmed:pagination749-56lld:pubmed
pubmed-article:1830034pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:meshHeadingpubmed-meshheading:1830034-...lld:pubmed
pubmed-article:1830034pubmed:year1991lld:pubmed
pubmed-article:1830034pubmed:articleTitleThe effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines.lld:pubmed
pubmed-article:1830034pubmed:affiliationDepartment of Oncology, Free University Hospital, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:1830034pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1830034pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1830034lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1830034lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1830034lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1830034lld:pubmed